

# K J Ewer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2311955/publications.pdf>

Version: 2024-02-01

115  
papers

18,881  
citations

44069

48  
h-index

30087

103  
g-index

121  
all docs

121  
docs citations

121  
times ranked

22376  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial. <i>Lancet Microbe</i> , The, 2022, 3, e11-e20.	7.3	25
2	Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria. <i>Frontiers in Immunology</i> , 2022, 13, 795463.	4.8	6
3	Vaccines against SARS-CoV-2. , 2022, , 201-222.		0
4	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. <i>JCI Insight</i> , 2022, 7, .	5.0	6
5	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	5.0	26
6	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet</i> , The, 2021, 397, 99-111.	13.7	3,887
7	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	30.7	265
8	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	30.7	473
9	Characterisation of the T-cell response to Ebola virus glycoprotein amongst survivors of the 2013-16 West Africa epidemic. <i>Nature Communications</i> , 2021, 12, 1153.	12.8	10
10	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet</i> , The, 2021, 397, 881-891.	13.7	979
11	Safety and Immunogenicity of Adenovirus and Poxvirus Vected Vaccines against a Mycobacterium Avium Complex Subspecies. <i>Vaccines</i> , 2021, 9, 262.	4.4	3
12	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet</i> , The, 2021, 397, 1351-1362.	13.7	540
13	Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. <i>Lancet</i> , The, 2021, 397, 1809-1818.	13.7	253
14	A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial. <i>Nature Communications</i> , 2021, 12, 4636.	12.8	31
15	Efficacy and Safety of a Modified Vaccinia Ankara-NP+M1 Vaccine Combined with QIV in People Aged 65 and Older: A Randomised Controlled Clinical Trial (INVICTUS). <i>Vaccines</i> , 2021, 9, 851.	4.4	6
16	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , the, 2021, 8, e474-e485.	4.7	190
17	A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults. <i>PLoS ONE</i> , 2021, 16, e0256980.	2.5	10
18	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T <sub>H</sub> 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	12.4	80

#	ARTICLE	IF	CITATIONS
19	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	30.7	900
20	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	13.7	214
21	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	13.7	2,080
22	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	13.7	1,196
23	Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	31
24	The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. <i>Immunology</i> , 2020, 160, 223-232.	4.4	86
25	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 816-826.	9.1	182
26	Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. <i>Journal of Infectious Diseases</i> , 2019, 219, 1187-1197.	4.0	59
27	Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine. <i>Vaccines</i> , 2019, 7, 40.	4.4	19
28	Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line. <i>Vaccines</i> , 2019, 7, 33.	4.4	23
29	OC 8552â€¦EFFICACY OF THE CHAD63-MVC ME-TRAP VECTORED MALARIA VACCINE CANDIDATE IN 5â€“17 MONTHS OLD INFANTS AND CHILDREN IN BURKINA FASO. <i>BMJ Global Health</i> , 2019, 4, A13.1-A13.	4.7	0
30	Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus. <i>Cell Reports</i> , 2019, 29, 2537-2545.e3.	6.4	7
31	Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. <i>Scientific Reports</i> , 2018, 8, 3390.	3.3	34
32	First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children. <i>PLoS ONE</i> , 2018, 13, e0208328.	2.5	53
33	CXCR3+ T Follicular Helper Cells Induced by Co-Administration of RTS,S/AS01B and Viral-Vectored Vaccines Are Associated With Reduced Immunogenicity and Efficacy Against Malaria. <i>Frontiers in Immunology</i> , 2018, 9, 1660.	4.8	26
34	Prime and target immunization protects against liver-stage malaria in mice. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	68
35	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. <i>Npj Vaccines</i> , 2018, 3, 49.	6.0	51
36	Methods for Measuring T-Cell Memory to Vaccination: From Mouse to Man. <i>Vaccines</i> , 2018, 6, 43.	4.4	24

#	ARTICLE	IF	CITATIONS
37	Activation-induced Markers Detect Vaccine-Specific CD4+ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials. <i>Vaccines</i> , 2018, 6, 50.	4.4	54
38	Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with <i>Plasmodium falciparum</i> Circumsporozoite Protein Antigens. <i>Journal of Immunology</i> , 2018, 201, 1315-1326.	0.8	30
39	Assessment of the <i>Plasmodium falciparum</i> Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine. <i>Infection and Immunity</i> , 2017, 85, .	2.2	16
40	Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants. <i>Molecular Therapy</i> , 2017, 25, 547-559.	8.2	34
41	A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160295.	4.0	33
42	Cryopreservation-related loss of antigen-specific IFN $\gamma$ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. <i>Vaccine</i> , 2017, 35, 1898-1906.	3.8	40
43	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 3020-3032.	3.3	67
44	Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M $\alpha$ , $\beta$ . <i>Vaccine</i> , 2017, 35, 6208-6217.	3.8	27
45	An in vitro assay to measure antibody-mediated inhibition of <i>P. berghei</i> sporozoite invasion against <i>P. falciparum</i> antigens. <i>Scientific Reports</i> , 2017, 7, 17011.	3.3	15
46	Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial. <i>Frontiers in Immunology</i> , 2017, 8, 1551.	4.8	23
47	IMMUNOGENICITY OF MALARIA-VECTORED VACCINES IS NOT AFFECTED BY CO-ADMINISTRATION WITH ROUTINE EPI VACCINES IN A RANDOMISED CONTROLLED TRIAL IN GAMBIAN INFANTS AND NEONATES. <i>BMJ Global Health</i> , 2017, 2, A30.3-A31.	4.7	0
48	Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against <i>Plasmodium falciparum</i> Infection in Adults in Senegal. <i>PLoS ONE</i> , 2016, 11, e0167951.	2.5	46
49	Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw031.	0.9	13
50	Safety and Immunogenicity of Novel Adenovirus Type 26 $\alpha$ and Modified Vaccinia Ankara $\alpha$ Vectored Ebola Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1610.	7.4	266
51	Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. <i>Molecular Therapy</i> , 2016, 24, 1470-1477.	8.2	52
52	Viral vectors as vaccine platforms: from immunogenicity to impact. <i>Current Opinion in Immunology</i> , 2016, 41, 47-54.	5.5	137
53	Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01 $\beta$ With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. <i>Journal of Infectious Diseases</i> , 2016, 214, 772-781.	4.0	96
54	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016, 374, 1635-1646.	27.0	295

#	ARTICLE	IF	CITATIONS
55	Identification of Immunodominant Responses to the Plasmodium falciparum Antigens PfUIS3, PflSA1 and PflSAP2 in Multiple Strains of Mice. PLoS ONE, 2015, 10, e0144515.	2.5	5
56	Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. Journal of Infectious Diseases, 2015, 211, 1076-1086.	4.0	110
57	Comparative assessment of vaccine vectors encoding ten malaria antigens identifies two protective liver-stage candidates. Scientific Reports, 2015, 5, 11820.	3.3	49
58	Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against <i>Plasmodium falciparum</i> infection in Kenyan adults. Science Translational Medicine, 2015, 7, 286re5.	12.4	113
59	Progress with viral vectored malaria vaccines: A multi-stage approach involving 'unnatural immunity'. Vaccine, 2015, 33, 7444-7451.	3.8	53
60	Safety and immunogenicity of the heterologous prime-boost Ebolavirus vaccine regimen CHAD3-EBO Z and MVA-BN <sup>®</sup> FILO in healthy UK adults. Journal of Infection, 2015, 71, 688.	3.3	0
61	Development of an In Vitro Assay and Demonstration of Plasmodium berghei Liver-Stage Inhibition by TRAP-Specific CD8 <sup>+</sup> T Cells. PLoS ONE, 2015, 10, e0119880.	2.5	17
62	Heterologous Prime-Boost Schedules of Replication-Defective Adenovirus Serotype 26 and Modified Vaccinia Virus Ankara Vector Vaccines Expressing Ebola Virus Glycoprotein Are Immunogenic and Well Tolerated in Healthy Adults. Open Forum Infectious Diseases, 2015, 2, .	0.9	1
63	Correction for Năbi et al., Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors. Vaccine Journal, 2014, 21, 1376-1376.	3.1	0
64	Development of an in vitro Plasmodium parasite killing assay for the evaluation of cell-mediated immune responses following vaccination with pre-erythrocytic malaria vaccine candidates. Malaria Journal, 2014, 13, .	2.3	1
65	Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults. Malaria Journal, 2014, 13, .	2.3	0
66	Co-infection with Schistosoma haematobium modulates the gene expression profile of malaria infection in schoolchildren in Gabon. Malaria Journal, 2014, 13, .	2.3	0
67	Analysis of human B cell responses following C<sub>h</sub>Ad63<sub>A</sub>MVA MSP<sub>1</sub> and AMA<sub>1</sub> immunization and controlled malaria infection. Immunology, 2014, 141, 628-644.	4.4	43
68	Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children. Malaria Journal, 2014, 13, .	2.3	0
69	Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors. Vaccine Journal, 2014, 21, 901-903.	3.1	12
70	Translating the Immunogenicity of Prime-boost Immunization With ChAd63 and MVA ME-TRAP From Malaria Naïve to Malaria-endemic Populations. Molecular Therapy, 2014, 22, 1992-2003.	8.2	49
71	Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure. PLoS ONE, 2014, 9, e107903.	2.5	65
72	A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and with MVA CS. PLoS ONE, 2014, 9, e115161.	2.5	48

#	ARTICLE	IF	CITATIONS
73	Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. <i>Nature Communications</i> , 2013, 4, 2836.	12.8	256
74	Assessment of Immune Interference, Antagonism, and Diversion following Human Immunization with Biallelic Blood-Stage Malaria Viral-Vectored Vaccines and Controlled Malaria Infection. <i>Journal of Immunology</i> , 2013, 190, 1135-1147.	0.8	23
75	Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with <i>Plasmodium falciparum</i> Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults. <i>PLoS ONE</i> , 2013, 8, e57726.	2.5	64
76	Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector. <i>Journal of Infectious Diseases</i> , 2012, 205, 772-781.	4.0	194
77	Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species. <i>Science Translational Medicine</i> , 2012, 4, 115ra2.	12.4	257
78	ChAd63-MVA vectorized Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans. <i>Molecular Therapy</i> , 2012, 20, 2355-2368.	8.2	196
79	Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the <i>Plasmodium falciparum</i> Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors. <i>PLoS ONE</i> , 2012, 7, e31208.	2.5	157
80	Clinical Evaluation Of New Viral Vectored Vaccines Targeting The <i>Plasmodium Falciparum</i> Blood-Stage Antigens; Msp1 And Ama1. <i>Journal of Infection</i> , 2011, 63, 492-493.	3.3	0
81	Viral vectors as vaccine platforms: deployment in sight. <i>Current Opinion in Immunology</i> , 2011, 23, 377-382.	5.5	188
82	Phase Ia Clinical Evaluation of the <i>Plasmodium falciparum</i> Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors. <i>Molecular Therapy</i> , 2011, 19, 2269-2276.	8.2	156
83	Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. <i>Clinical Infectious Diseases</i> , 2011, 52, 1-7.	5.8	424
84	Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1/Alhydrogel+CPG 7909. <i>PLoS ONE</i> , 2011, 6, e22271.	2.5	84
85	Prime-boost vectored malaria vaccines: Progress and prospects. <i>Hum Vaccin</i> , 2010, 6, 78-83.	2.4	184
86	Gene expression profiling and antigen mining of the tuberculin production strain <i>Mycobacterium bovis</i> AN5. <i>Veterinary Microbiology</i> , 2009, 133, 272-277.	1.9	5
87	Potency assays for novel T-cell-inducing vaccines against malaria. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 72-80.	2.8	23
88	Screening of Highly Expressed <i>Mycobacterium</i> Genes Identifies Rv3615c as a Useful Differential Diagnostic Antigen for the <i>Mycobacterium tuberculosis</i> Complex. <i>Infection and Immunity</i> , 2008, 76, 3932-3939.	2.2	95
89	Characterization of two in vivo-expressed methyltransferases of the <i>Mycobacterium tuberculosis</i> complex: antigenicity and genetic regulation. <i>Microbiology (United Kingdom)</i> , 2008, 154, 1059-1067.	1.8	13
90	Is Interleukin-4 $\gamma$ 3 Splice Variant Expression in Bovine Tuberculosis a Marker of Protective Immunity?. <i>Infection and Immunity</i> , 2007, 75, 3006-3013.	2.2	20

#	ARTICLE	IF	CITATIONS
91	T-Cell-Based Diagnosis of Neonatal Multidrug-Resistant Latent Tuberculosis Infection. <i>Pediatrics</i> , 2007, 119, e1-e5.	2.1	41
92	Should Individuals Who Are Tuberculin Skin Test Negative and Positive to RD1-IFN- $\gamma$ Assay Receive Preventive Therapy?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 199-199.	5.6	1
93	Impact of a T cell-based blood test for tuberculosis infection on clinical decision-making in routine practice. <i>Journal of Infection</i> , 2007, 54, e169-e174.	3.3	22
94	Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. <i>Leukemia</i> , 2006, 20, 379-381.	7.2	17
95	Dynamic Antigen-specific T-Cell Responses after Point-Source Exposure to <i>Mycobacterium tuberculosis</i> . <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 831-839.	5.6	196
96	Repeated tuberculin testing does not induce false positive ELISPOT results. <i>Thorax</i> , 2006, 61, 180-180.	5.6	44
97	Antigen Mining with Iterative Genome Screens Identifies Novel Diagnostics for the <i>Mycobacterium tuberculosis</i> Complex. <i>Vaccine Journal</i> , 2006, 13, 90-97.	3.1	19
98	Ex Vivo Characterization of Early Secretory Antigenic Target 6-Specific T Cells at Sites of Active Disease in Pleural Tuberculosis. <i>Clinical Infectious Diseases</i> , 2005, 40, 184-187.	5.8	155
99	Enzyme-linked Immunospot and Tuberculin Skin Testing to Detect Latent Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005, 172, 1161-1168.	5.6	117
100	Effect of BCG vaccination on risk of <i>Mycobacterium tuberculosis</i> infection in children with household tuberculosis contact: a prospective community-based study. <i>Lancet, The</i> , 2005, 366, 1443-1451.	13.7	266
101	T Cell-Based Tracking of Multidrug Resistant Tuberculosis Infection after Brief Exposure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 288-295.	5.6	131
102	Characterization of a <i>Mycobacterium tuberculosis</i> Peptide That Is Recognized by Human CD4+ and CD8+ T Cells in the Context of Multiple HLA Alleles. <i>Journal of Immunology</i> , 2004, 173, 1966-1977.	0.8	82
103	Evaluation of T-Cell Responses to Novel RD1- and RD2-Encoded <i>Mycobacterium tuberculosis</i> Gene Products for Specific Detection of Human Tuberculosis Infection. <i>Infection and Immunity</i> , 2004, 72, 2574-2581.	2.2	75
104	Diagnosis of tuberculosis in South African children with a T cell-based assay: a prospective cohort study. <i>Lancet, The</i> , 2004, 364, 2196-2203.	13.7	353
105	Early Diagnosis of Subclinical Multidrug-Resistant Tuberculosis. <i>Annals of Internal Medicine</i> , 2004, 140, 709.	3.9	59
106	Comparison of T-cell-based assay with tuberculin skin test for diagnosis of <i>Mycobacterium tuberculosis</i> infection in a school tuberculosis outbreak. <i>Lancet, The</i> , 2003, 361, 1168-1173.	13.7	578
107	Diagnosis of tuberculosis. <i>Lancet, The</i> , 2003, 361, 2081-2082.	13.7	3
108	Diagnosis of tuberculosis. <i>Lancet, The</i> , 2003, 361, 2082-2083.	13.7	1



#	ARTICLE	IF	CITATIONS
109	Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. <i>Aids</i> , 2002, 16, 2285-2293.	2.2	276
110	Enumeration of T Cells Specific for RD1-Encoded Antigens Suggests a High Prevalence of Latent <i>Mycobacterium tuberculosis</i> Infection in Healthy Urban Indians. <i>Journal of Infectious Diseases</i> , 2001, 183, 469-477.	4.0	335
111	Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). <i>SSRN Electronic Journal</i> , 0, , .	0.4	36
112	Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine. <i>SSRN Electronic Journal</i> , 0, , .	0.4	10
113	Safety and Immunogenicity of the ChAdox1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 in HIV Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	6
114	Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222). <i>SSRN Electronic Journal</i> , 0, , .	0.4	23
115	High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-M, with Seasonal Administration to Children in Burkina Faso. <i>SSRN Electronic Journal</i> , 0, , .	0.4	12